14
Participants
Start Date
October 31, 2006
Primary Completion Date
September 30, 2011
Study Completion Date
November 30, 2013
Allogeneic Pancreatic Islet Cells
Preparation of allogeneic pancreatic islet cells injected into the portal vein of the liver
Deoxyspergualin
An anti-inflammatory agent that blocks proinflammatory cytokine production and inhibits T-cells and B-cells and affects antigen presenting cells.
Antithymocyte globulin
Immunosuppressive that selectively depletes activated T-cells and depletes resting T-cells in a dose-dependent manner.
Daclizumab or basiliximab
Will replace antithymocyte globulin in all islet transplantations after the first one
Sirolimus
Maintenance immunosuppressive therapy
Tacrolimus
Maintenance immunosuppressive therapy
Etanercept
Blocks TNF-alpha which is toxic to islet cells
University of Minnesota, Minneapolis
Northwestern University, Chicago
University of Californinia, San Francisco, San Francisco
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
National Institute of Allergy and Infectious Diseases (NIAID)
NIH